Skip to main content
OpenTrials
Completed

NCT Number: NCT01083199

Global Performance Evaluation of the AMS CONTINUUM™ Device

1. To evaluate Device performance in providing mucosa to mucosa apposition to facilitate sustainable vesico-urethral anastomosis during a radical prostatectomy procedure. 2. To assess clinical outcomes of the Device in facilitating the vesico-urethral anastomosis following a radical prostatectomy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prostate Cancer Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

40 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 4

Primary location

University of Patras, Rio-Patras, Greece

Loading trial locations.

About this study

Radical prostatectomy (RP) is the most utilized surgical treatment option for localized prostate cancer due to the multi-focal nature of the disease. RP is most suitable for otherwise healthy men whose cancer is limited to a small area. The RP procedure involves removing the prostate gland, seminal vesicles and nearby lymph nodes. One of the most technically challenging and critical aspects in all of these surgical approaches is reconstruction of the interrupted urinary tract by hand sewing the vesico-urethral anastomosis. This is where the bladder neck is sewn to the urethra after the prostate has been removed.

CONTINUUM™ (study Device) is to be used as part of the RP procedure by facilitating the approximation of the bladder neck and urethral stump. The Device brings together and holds the tissue in place until adequate natural healing of the vesico-urethral anastomosis occurs thereby minimizing extravasation. The Device also provides a conduit for drainage of urine from the bladder out the urethra during tissue healing.

The concept of the CONTINUUM™ device and the feasibility of its operation have been successfully tested in animal and human studies. Pilot clinical studies in the United States (G060095) found that the majority of subjects who received and were discharged with the Device demonstrated a water-tight vesico-urethral anastomosis at the first Device removal visit. Additionally, no unanticipated adverse device effects (UADEs) were reported. The focus of the proposed study is to further verify the performance of the Device in global research centers.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All males ≥ 40 years old who are indicated for a radical prostatectomy will be eligible to participate in the study

Exclusion criteria

  • If contraindicated for surgery
  • Inability to understand the study or a history of non-compliance with medical advice
  • Unwilling or unable to sign an Informed Consent Form (ICF)
  • A history of:
  • Recurrent urinary tract infections (UTI)
  • Recurrent stricture disease
  • Neurological disease with a history of bladder dysfunction (e.g., Parkinson's disease)
  • Uncontrolled insulin-dependent diabetes
  • Chemotherapy within the past 6 months
  • Non-topical steroid use within the past 6 months
  • Allergy to nitinol, nickel, titanium or silicone

Treatment and study plan

CONTINUUM™

Device

Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.

Other names: Anastomosis Device

Primary outcomes

  1. Successful Device Placement

    Time frame: During Radical Prostatectomy

    Successful Device placement was defined as the establishment of a water-tight anastomosis immediately post-Device placement.

  2. Functionally Adequate Vesico-urethral Anastomosis Within 21 Days Post-procedure in Subjects With Successful Device Placement

    Time frame: 7-21 days post-Device placement

    Device removal was first attempted at the 7-day window; if extravasation was noted, the subject returned for a second attempt at the 14-day window. If extravasation was noted at the first and second attempts, the subject could then return for a 3rd and final removal at the 21-day window.

    The following defines the timeframe of each removal attempt:

    • 7-day window (7-10 days post-implant)
    • 14-day window (13-15 days post-implant)
    • 21-day window (19-21 days post-implant)

Secondary outcomes

  1. Intraoperative/Postoperative Parameters

    Time frame: At Device placement

  2. Percentage of Subjects Demonstrating Functionally Adequate Anastomosis at the 1st and 2nd Device Removal Visits

    Time frame: 7 and 14 days post-Device placement

  3. Incontinence Rate and I-QOL Score

    Time frame: Baseline, 6-week, 6 and 12-month evaluations

  4. Bladder Neck Contracture (BNC) Rate

    Time frame: Subjects that develop BNC between the scheduled follow-up visits at 6 weeks, 6 and 12 months post-device removal

Sponsors and collaborators

Lead sponsor

American Medical Systems

Industry

Registry information

Official study title

Global Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy

Important dates

Study start
2007
Primary completion
2010
Study completion
2010
First posted
Mar 9, 2010
Registry last updated
Apr 12, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.